Long‑term safety and drug survival of biologic therapies in psoriasis patients with and without diabetes mellitus: a comparative analysis and risk factor assessment

Published: 12 October 2026| Version 1 | DOI: 10.17632/ywb9xtbzb3.1
Contributors:
yizhang liu,
, Haizhen Wang,
,
,

Description

Background: Long-term biologic safety and drug survival in psoriasis patients with and without diabetes remain poorly characterized. Objectives: To compare 96-week treatment-related adverse events (TRAEs) and drug survival between psoriasis patients with and without diabetes, and to identify risk factors for these outcomes in diabetic patients. Methods: This retrospective study evaluated biologic‑treated psoriatic patients at Xiangya Hospital, stratified into non‑diabetic and diabetic groups by diabetes status. Results: A total of 1,245 patients were included (1,007 non‑diabetic, 238 diabetic). The cumulative incidence of any TRAE was significantly higher in the diabetic group. The diabetic group also showed higher rates of injection-site reactions, urticaria, fungal infections, ≥2 TRAEs, and TRAE-related discontinuation. Older age, higher fasting plasma glucose (FPG), and interleukin‑17A inhibitor use were independent risk factors for TRAEs in the diabetic group. Drug survival was significantly lower in the diabetic group, with a higher proportion of discontinuations due to primary failure. Higher psoriasis area and severity index, higher FPG, lower educational attainment, and current smoking were independent risk factors for discontinuation in the diabetic group. Limitations: Single-center. Conclusion: Risk factors identified enable risk stratification and may optimize the long-term safety and persistence of biologic therapy in psoriasis patients with diabetes.

Files

Categories

Psoriasis

Licence